Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 11, 2013, Pages 1607-1621

  Mohamed, Radwa A ^a   Abass, Haidy A ^a   Attia, Mohamed A ^b   Heikal, Ola A ^a  

^a German University in Cairo   (Egypt)

^b Assiut University   (Egypt)

Author keywords

gastric emptying percent; high shear homogenization; metoclopramide; solid lipid nanoparticle loaded suppositories; solid lipid nanoparticles

Indexed keywords

CREMOPHOR; GLYCEROL BEHENATE; METOCLOPRAMIDE; PHENOLSULFONPHTHALEIN; POLOXAMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; SUPPOSITORY BASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISPERSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELTING POINT; MULTIPLE DRUG DOSE; NAUSEA AND VOMITING; NONHUMAN; PARTICLE SIZE; RAT; STOMACH EMPTYING; SUPPOSITORY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

GASTRIC EMPTYING PERCENT; HIGH-SHEAR HOMOGENIZATION; METOCLOPRAMIDE; SOLID LIPID NANOPARTICLE-LOADED SUPPOSITORIES; SOLID LIPID NANOPARTICLES;

ADMINISTRATION, RECTAL; ANIMALS; ANTIEMETICS; DELAYED-ACTION PREPARATIONS; DOPAMINE ANTAGONISTS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FATTY ACIDS; FEMALE; GASTRIC EMPTYING; METOCLOPRAMIDE; NANOPARTICLES; NAUSEA; PARTICLE SIZE; POLOXAMER; RATS; SUPPOSITORIES; SURFACE-ACTIVE AGENTS; VOMITING;

EID: 84886101387     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12136     Document Type: Article

References (48)

1. Jigisha K, et al. Cyclosporine A loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Curr Drug Deliv 2008; 5: 64-69.
2. Sharma A, et al. Development of a novel method for fabrication of solid lipid nanoparticles: using high shear homogenization and ultrasonication. RJPBCS 2010; 1: 265-274.
3. Abbasalipourkabir R, et al. Characterization and stability of nanostructured lipid carriers as drug delivery system. Pak J Biol Sci 2012; 15: 141-146.
4. Müller RH, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
5. Schwarz C, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J Control Release 1994; 30: 83-96.
6. Westesen K, et al. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1994; 48: 223-236.
7. Mehnert W, Mader K,. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
8. Wissing SA, et al. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-1272.
9. Joshi MD, Müller RH,. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009; 71: 161-172.
10. Shaji J, Jain V,. Solid lipid nanoparticles: a novel carrier for chemotherapy. Int J Pharm Pharm Sci 2010; 2: 8-17.
11. Mullen zur A,. Solid lipid nanoparticles with prolonged drug liberation: production, long-term stability, characterization, release behavior and mechanisms. PhD Thesis, Free University of Berlin 1996 [In German].
12. Muller RH, et al. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release 1997; 47: 261-269.
13. Westesen K, et al. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993; 93: 189-199.
14. Carter B, Fedorowicz Z,. Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework. BMJ Open 2012; 2: 1-13.
15. Rao AS, Camilleri M,. Review article: metoclopramide and tardive dyskinesia. Aliment pharmacol Ther 2010; 31: 11-19.
16. Singh S, et al. Gastroretentive drug delivery system of metoclopramide hydrochloride: formulation and in vitro evaluation. Curr Drug Deliv 2007; 4: 269-275.
17. British Pharmacopoeia Commission. Metoclopramide hydrochloride. Br Pharm 2009; 2: 3921-3924.
18. Fass R, et al. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther 2009; 30: 301-306.
19. Jayashri G, et al. Formulation and in vitro evaluation of taste masked orodispersible tablet of metoclopramide hydrochloride. Int J PharmTech Res 2010; 2: 1827-1835.
20. Nehal S, et al. Fast dissolving tablets:preparation, characterization and evaluation: an overview. Int J Pharm Sci Rev Res 2010; 4: 87-96.
21. Van Hoogdalem E, et al. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 1991; 21: 11-26.
22. Uzunkaya G, Berdisadi N,. In vitro drug liberation and kinetics of sustained release indomethacin suppository. Farmaco 2003; 58: 509-512.
23. Cossu M, et al. A new sensitive reversed-phase high performance liquid chromatography method for the quantitative determination of metoclopramide in canine plasma. Anal Lett 2008; 41: 767-778.
24. Abdelbary G, Fahmy RH,. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 2009; 10: 211-219.
25. Gold M, et al. Suppository Development and Production, Pharmaceutical Dosage Forms, Disperse Systems (2), 2nd edn. New York, NY: Marcel Dekker, Inc, 1996.
26. Gupta YK, Geeta C,. Effect of antiemetic drugs on decrease in gastric emptying in experimental model of motion sickness in rats. Acta Pharmacol Sin 2003; 24: 296-300.
27. Westesen K,. Particles with modified physic-chemical properties, their preparation and uses. 2001; 197: 349. US patent 6
28. Li Y, et al. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. Int J Biol Macromol 2006; 38: 296-299.
29. Li P, et al. Effect of combined use of nonionic surfactants on formulation of oil in water emulsion. Int J Pharm 2005; 288: 27-34.
30. Song H, et al. Characterization and in vivo evaluation of novel lipid chlorambucil nanospheres prepared using a mixture of emulsifiers for parentral administration. Int J Nanomedicine 2010; 5: 933-942.
31. Venkateswarlu V, Manjunath K,. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95: 627-638.
32. Luo Y, et al. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 2006; 114: 53-59.
33. Porter MR,. Handbook of Surfactants. London: Chapman Hall, 1994: 122-128.
34. Hou D, et al. The production and characterization of solid lipid nanoparticles (SLNs). Biomaterials 2003; 24: 1781-1785.
35. Esposito E, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 2008; 25: 1521-1530.
36. Jenning V, et al. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-126.
37. Lim S, Kim C,. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 2002; 243: 135-146.
38. Reddy LH, Murthy RS,. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS PharmSciTech 2005; 6: 158-166.
39. Gheorghe F, et al. An intelligent multicompartmental system based on thermo-sensitive starch microspheres for temperature-controlled release of drugs. Biomed Microdevices 2010; 12: 693-704.
40. Zur Muhlen A, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998; 452: 149-155.
41. Yang YY, et al. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001; 22: 231-241.
42. Quintanar-Guerrero D, et al. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 2005; 26: 211-218.
43. Mishra DN, et al. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. Chem Pharm Bull 2006; 54: 99-102.
44. Aulton ME,. Rectal and Vaginal Drug Delivery, Pharmaceutics: The Science of Dosage Form Design, 2nd edn. Edinburgh, UK: Churchill Livingstone, 2002.
45. Lootvoet G, et al. Study on release of indomethacin from suppositories: in vitro- in vivo correlation. Int J Pharm 2002; 85: 113-120.
46. Yong-Ling L, et al. Pica-A model of nausea? Species differences in response to cisplatin. J Physbeh 2005; 85: 271-277.
47. Thornton WE, et al. Gastrointestinal motility in space motion sickness. Aviat Space Environ Med 1987; 58: 16-21.
48. Sharma SS, Gupta YK,. Effects of antioxidants on cisplatin induced delay in gastric emptying in rats. Environ Toxicol Pharmacol 1997; 3: 41-46.